We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Universal Insurance Holdings
UVE
$1.21B
| $328K | 0.01% |
+20,505
| New | +$319K |
|
102
CareTrust REIT
CTRE
$10.1B
| $326K | 0.01% |
+14,554
| New | +$322K |
|
103
Merck
MRK
$323B
| $323K | 0.01% |
+2,960
| New | +$307K |
|
104
Utz Brands
UTZ
$1.25B
| $320K | 0.01% |
+19,732
| New | +$260K |
|
|
RCM
105
DELISTED
R1 RCM Inc. Common Stock
RCM
| $315K | 0.01% |
+29,840
| New | +$338K |
|
106
Huron Consulting
HURN
$1.89B
| $315K | 0.01% |
+3,065
| New | +$315K |
|
107
Trinity Industries
TRN
$2.95B
| $314K | 0.01% |
+11,821
| New | +$284K |
|
108
Hexcel
HXL
$8.28B
| $312K | 0.01% |
+4,232
| New | +$286K |
|
109
Quaker Houghton
KWR
$2.63B
| $306K | 0.01% |
+1,434
| New | +$247K |
|
110
Acadia Pharmaceuticals
ACAD
$4.35B
| $305K | 0.01% |
+9,728
| New | +$232K |
|
111
Marvell Technology
MRVL
$170B
| $304K | 0.01% |
+5,048
| New | +$273K |
|
|
IPG
112
DELISTED
Interpublic Group of Companies
IPG
| $304K | 0.01% |
+9,324
| New | +$281K |
|
113
iHeartMedia
IHRT
$547M
| $302K | 0.01% |
+113,251
| New | +$286K |
|
114
Alnylam Pharmaceuticals
ALNY
$37.2B
| $301K | 0.01% |
+1,574
| New | +$268K |
|
115
Incyte
INCY
$23.7B
| $293K | 0.01% |
+4,665
| New | +$264K |
|
116
NewAmsterdam Pharma Warrant
NAMSW
$87.4M
| $290K | 0.01% |
92,787
| – | – |
|
117
Mettler-Toledo International
MTD
$27B
| $289K | 0.01% |
+238
| New | +$257K |
|
118
Madrigal Pharmaceuticals
MDGL
$12.7B
| $289K | 0.01% |
+1,247
| New | +$218K |
|
119
Target
TGT
$63.7B
| $288K | 0.01% |
+2,024
| New | +$247K |
|
120
Janus International
JBI
$732M
| $287K | 0.01% |
+21,961
| New | +$234K |
|
121
Carriage Services
CSV
$635M
| $286K | 0.01% |
+11,444
| New | +$269K |
|
122
Fulgent Genetics
FLGT
$556M
| $284K | 0.01% |
+9,829
| New | +$263K |
|
123
CONMED
CNMD
$1.31B
| $280K | 0.01% |
+2,556
| New | +$264K |
|
124
Life Time Group Holdings
LTH
$9.74B
| $276K | 0.01% |
+18,308
| New | +$263K |
|
125
Sonic Automotive
SAH
$3.25B
| $275K | 0.01% |
+4,896
| New | +$245K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.